Friday, 13 April 2012

Zyloric Tablets 100mg, 300mg





1. Name Of The Medicinal Product



Zyloric 100 mg Tablets



Zyloric 300 mg Tablets


2. Qualitative And Quantitative Composition



Allopurinol 100 mg (Zyloric Tablets)



Allopurinol 300 mg (Zyloric-300 Tablets)



3. Pharmaceutical Form



Tablet



4. Clinical Particulars



4.1 Therapeutic Indications



Zyloric is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. Zyloric is indicated for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.



Zyloric is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.



4.2 Posology And Method Of Administration



Dosage in Adults: Zyloric should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor (see Dosage in renal impairment). The following dosage schedules are suggested:



100 to 200 mg daily in mild conditions,



300 to 600 mg daily in moderately severe conditions,



700 to 900 mg daily in severe conditions.



If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used.



Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.



Dosage in the elderly: In the absence of specific data, the lowest dosage which produces satisfactory urate reduction should be used. Particular attention should be paid to advice in Dosage in renal impairment and Precautions and Warnings.



Dosage in renal impairment: Since allopurinol and its metabolites are excreted by the kidney, impaired renal function may lead to retention of the drug and/or its metabolites with consequent prolongation of plasma half-lives. In severe renal insufficiency, it may be advisable to use less than 100 mg per day or to use single doses of 100mg at longer intervals than one day.



If facilities are available to monitor plasma oxipurinol concentrations, the dose should be adjusted to maintain plasma oxipurinol levels below 100 micromol/litre (15.2 mg/litre).



Allopurinol and its metabolites are removed by renal dialysis. If dialysis is required two to three times a week consideration should be given to an alternative dosage schedule of 300-400 mg Zyloric immediately after each dialysis with none in the interim.



Dosage in hepatic impairment: Reduced doses should be used in patients with hepatic impairment. Periodic liver function tests are recommended during the early stages of therapy.



Treatment of high urate turnover conditions, e.g. neoplasia, Lesch-Nyhan syndrome: It is advisable to correct existing hyperuricaemia and/or hyperuricosuria with Zyloric before starting cytotoxic therapy. It is important to ensure adequate hydration to maintain optimum diuresis and to attempt alkalinisation of urine to increase solubility of urinary urate/uric acid. Dosage of Zyloric should be at the lower end of the recommended dosage schedule.



If urate nephropathy or other pathology has compromised renal function, the advice given in Dosage in renal impairment should be followed.



These steps may reduce the risk of xanthine and/or oxipurinol deposition complicating the clinical situation. See also Drug Interactions And Adverse Reactions.



Monitoring Advice: The dosage should be adjusted by monitoring serum urate concentrations and urinary urate/uric acid levels at appropriate intervals.



Instructions for Use: Zyloric may be taken orally once a day after a meal. It is well tolerated, especially after food. Should the daily dosage exceed 300 mg and gastrointestinal intolerance be manifested, a divided doses regimen may be appropriate.



4.3 Contraindications



Zyloric should not be administered to individuals known to be hypersensitive to allopurinol or to any of the components of the formulation.



4.4 Special Warnings And Precautions For Use



Zyloric should be withdrawn immediately when a skin rash or other evidence of sensitivity occurs as this could result in more serious hypersensitivity reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) (see Adverse Reactions – Immune system disorders and Skin and subcutaneous tissue disorders).



Reduced doses should be used in patients with hepatic or renal impairment. Patients under treatment for hypertension or cardiac insufficiency, for example with diuretics or ACE inhibitors, may have some concomitant impairment of renal function and allopurinol should be used with care in this group.



Asymptomatic hyperuricaemia per se is generally not considered an indication for use of Zyloric. Fluid and dietary modification with management of the underlying cause may correct the condition.



Acute gouty attacks: Allopurinol treatment should not be started until an acute attack of gout has completely subsided, as further attacks may be precipitated.



In the early stages of treatment with Zyloric, as with uricosuric agents, an acute attack of gouty arthritis may be precipitated. Therefore it is advisable to give prophylaxis with a suitable anti-inflammatory agent or colchicine for at least one month. The literature should be consulted for details of appropriate dosage and precautions and warnings.



If acute attacks develop in patients receiving allopurinol, treatment should continue at the same dosage while the acute attack is treated with a suitable anti-inflammatory agent.



Xanthine deposition: In conditions where the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. This risk may be minimised by adequate hydration to achieve optimal urine dilution.



Impaction of uric acid renal stones: Adequate therapy with Zyloric will lead to dissolution of large uric acid renal pelvic stones, with the remote possibility of impaction in the ureter.



Lactose intolerance: Zyloric tablets contain lactose and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



6 -mercaptopurine and azathioprine: Azathioprine is metabolised to 6-mercaptopurine which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with Zyloric, only one-quarter of the usual dose of 6-mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity.



Vidarabine (Adenine Arabinoside): Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilance is necessary, to recognise enhanced toxic effects.



Salicylates and uricosuric agents: oxipurinol, the major metabolite of allopurinol and itself therapeutically active, is excreted by the kidney in a similar way to urate. Hence, drugs with uricosuric activity such as probenecid or large doses of salicylate may accelerate the excretion of oxipurinol. This may decrease the therapeutic activity of Zyloric, but the significance needs to be assessed in each case.



Chlorpropamide: If Zyloric is given concomitantly with chlorpropamide when renal function is poor, there may be an increased risk of prolonged hypoglycaemic activity because allopurinol and chlorpropamide may compete for excretion in the renal tubule.



Coumarin anticoagulants



There have been rare reports of increased effect of warfarin and other coumarin anticoagulants when co-administered with allopurinol, therefore, all patients receiving anticoagulants must be carefully monitored.



Phenytoin: Allopurinol may inhibit hepatic oxidation of phenytoin but the clinical significance has not been demonstrated.



Theophylline: Inhibition of the metabolism of theophylline has been reported. The mechanism of the interaction may be explained by xanthine oxidase being involved in the biotransformation of theophylline in man. Theophylline levels should be monitored in patients starting or increasing allopurinol therapy.



Ampicillin/Amoxicillin: An increase in frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. The cause of the reported association has not been established. However, it is recommended that in patients receiving allopurinol an alternative to ampicillin or amoxicillin is used where available.



Cyclophosphamide, doxorubicin, bleomycin, procarbazine, mechloroethamine: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease (other than leukaemia), in the presence of allopurinol. However, in a well-controlled study of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechloroethamine (chlormethine hydrochloride) allopurinol did not appear to increase the toxic reaction of these cytotoxic agents.



Ciclosporin: Reports suggest that the plasma concentration of ciclosporin may be increased during concomitant treatment with allopurinol. The possibility of enhanced ciclosporin toxicity should be considered if the drugs are co-administered.



Didanosine: In healthy volunteers and HIV patients receiving didanosine, plasma didanosine Cmax and AUC values were approximately doubled with concomitant allopurinol treatment (300 mg daily) without affecting terminal half life. Co-administration of these 2 drugs is generally not recommended. If concomitant use is unavoidable, a dose reduction of didanosine may be required, and patients should be closely monitored.



4.6 Pregnancy And Lactation



There is inadequate evidence of safety of Zyloric in human pregnancy, although it has been in wide use for many years without apparent ill consequence.



Use in pregnancy only when there is no safer alternative and when the disease itself carries risk for the mother or unborn child.



Reports indicate that allopurinol and oxipurinol are excreted in human breast milk. Concentrations of 1.4mg/litre allopurinol and 53.7 mg/litre oxipurinol have been demonstrated in breast milk from woman taking Zyloric 300 mg/day. However, there are no data concerning the effects of allopurinol or its metabolites on the breast-fed baby.



4.7 Effects On Ability To Drive And Use Machines



Since adverse reactions such as somnolence, vertigo and ataxia have been reported in patients receiving allopurinol, patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that allopurinol does not adversely affect performance.



4.8 Undesirable Effects



For this product there is no modern clinical documentation which can be used as support for determining the frequency of undesirable effects. Undesirable effects may vary in their incidence depending on the dose received and also when given in combination with other therapeutic agents.



The frequency categories assigned to the adverse drug reactions below are estimates: for most reactions, suitable data for calculating incidence are not available. Adverse drug reactions identified through post-marketing surveillance were considered to be rare or very rare. The following convention has been used for the classification of frequency:














Very common







Common







Uncommon







Rare







Very rare




<1/10,000 (<0.01%)



Adverse reactions in association with Zyloric are rare in the overall treated population and mostly of a minor nature. The incidence is higher in the presence of renal and/or hepatic disorder.



Infections and infestations






Very rare




Furunculosis



Blood and lymphatic system disorders






Very rare




Agranulocytosis, aplastic anaemia, thrombocytopenia



Very rare reports have been received of thrombocytopenia, agranulocytosis and aplastic anaemia, particularly in individuals with impaired renal and/or hepatic function, reinforcing the need for particular care in this group of patients.



Immune system disorders








Uncommon




Hypersensitivity reactions




Very rare




Angioimmunoblastic lymphadenopathy



Serious hypersensitivity reactions, including skin reactions associated with exfoliation, fever, lymphadenopathy, arthralgia and/or eosinophilia including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis occur rarely (see Skin and subcutaneous tissue disorders). Associated vasculitis and tissue response may be manifested in various ways including hepatitis, renal impairment and very rarely, seizures. Very rarely acute anaphylactic shock has been reported. If such reactions do occur, it may be at any time during treatment, Zyloric should be withdrawn immediately and permanently.



Corticosteroids may be beneficial in overcoming hypersensitivity skin reactions. When generalised hypersensitivity reactions have occurred, renal and/or hepatic disorder has usually been present particularly when the outcome has been fatal.



Angioimmunoblastic lymphadenopathy has been described very rarely following biopsy of a generalised lymphadenopathy. It appears to be reversible on withdrawal of Zyloric.



Metabolism and nutrition disorders






Very rare




Diabetes mellitus, hyperlipidaemia



Psychiatric disorders






Very rare




Depression



Nervous system disorders






Very rare




Coma, paralysis, ataxia, neuropathy, paraesthesiae, somnolence, headache, taste perversion



Eye disorders






Very rare




Cataract, visual disorder, macular changes



Ear and labyrinth disorders






Very rare




Vertigo



Cardiac disorders






Very rare




Angina, bradycardia



Vascular disorders






Very rare




Hypertension



Gastrointestinal disorders








Uncommon




Vomiting, nausea




Very rare




Recurrent haematemesis, steatorrhoea, stomatitis, changed bowel habit



In early clinical studies, nausea and vomiting were reported. Further reports suggest that this reaction is not a significant problem and can be avoided by taking Zyloric after meals.



Hepatobiliary disorders








Uncommon




Asymptomatic increases in liver function tests




Rare




Hepatitis (including hepatic necrosis and granulomatous hepatitis)



Hepatic dysfunction has been reported without overt evidence of more generalised hypersensitivity.



Skin and subcutaneous tissue disorders










Common




Rash




Rare




Stevens-Johnson syndrome/toxic epidermal necrolysis




Very rare




Angioedema, fixed drug eruption, alopecia, discoloured hair



Skin reactions are the most common reactions and may occur at any time during treatment. They may be pruritic, maculopapular, sometimes scaly, sometimes purpuric and rarely exfoliative, such as Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN).



Zyloric should be withdrawn immediately should such reactions occur. After recovery from mild reactions, Zyloric may, if desired, be re-introduced at a small dose (e.g. 50mg/day) and gradually increased. If the rash recurs, Zyloric should be permanently withdrawn as more severe hypersensitivity may occur (see Immune system disorders).



The HLA-B*5801 allele has been has been identified as a genetic risk factor for allopurinol associated SJS/TEN in retrospective, case-control, pharmacogenetic studies in patients of Han Chinese, Japanese and European descent. Up to 20-30% of some Han Chinese, African and Indian populations carry the HLA-B*5801 allele whereas only 1-2% of Northern European, US European and Japanese patients are estimated to be HLA-B*5801 carriers. However, the use of genotyping as a screening tool to make decisions about treatment with allopurinol has not been established.



The clinical diagnosis of SJS/TEN remains the basis for decision making. If such reactions occur at any time during treatment, allopurinol should be withdrawn immediately and permanently.



Angioedema has been reported to occur with and without signs and symptoms of a more generalised hypersensitivity reaction.



Renal and urinary disorders






Very rare




Haematuria, uraemia



Reproductive system and breast disorders






Very rare




Male infertility, erectile dysfunction, gynaecomastia



General disorders and administration site conditions






Very rare




Oedema, general malaise, asthenia, fever



Fever has been reported to occur with and without signs and symptoms of a more generalised Zyloric hypersensitivity reaction (see Immune system disorders).



4.9 Overdose



Ingestion of up to 22.5 g allopurinol without adverse effect has been reported. Symptoms and signs including nausea, vomiting, diarrhoea and dizziness have been reported in a patient who ingested 20 g allopurinol. Recovery followed general supportive measures. Massive absorption of Zyloric may lead to considerable inhibition of xanthine oxidase activity, which should have no untoward effects unless affecting concomitant medication, especially with 6-mercaptopurine and/or azathioprine. Adequate hydration to maintain optimum diuresis facilitates excretion of allopurinol and its metabolites. If considered necessary haemodialysis may be used.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Allopurinol is a xanthine-oxidase inhibitor. Allopurinol and its main metabolite oxipurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. In addition to the inhibition of purine catabolism in some but not all hyperuricaemic patients, de novo purine biosynthesis is depressed via feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase. Other metabolites of allopurinol include allopurinol-riboside and oxipurinol-7 riboside.



5.2 Pharmacokinetic Properties



Allopurinol is active when given orally and is rapidly absorbed from the upper gastrointestinal tract. Studies have detected allopurinol in the blood 30-60 minutes after dosing. Estimates of bioavailability vary from 67% to 90%. Peak plasma levels of allopurinol generally occur approximately 1.5 hours after oral administration of Zyloric, but fall rapidly and are barely detectable after 6 hours. Peak levels of oxipurinol generally occur after 3-5 hours after oral administration of Zyloric and are much more sustained.



Allopurinol is negligibly bound by plasma proteins and therefore variations in protein binding are not thought to significantly alter clearance. The apparent volume of distribution of allopurinol is approximately 1.6 litre/kg which suggests relatively extensive uptake by tissues. Tissue concentrations of allopurinol have not been reported in humans, but it is likely that allopurinol and oxipurinol will be present in the highest concentrations in the liver and intestinal mucosa where xanthine oxidase activity is high.



Approximately 20% of the ingested allopurinol is excreted in the faeces. Elimination of allopurinol is mainly by metabolic conversion to oxipurinol by xanthine oxidase and aldehyde oxidase, with less than 10% of the unchanged drug excreted in the urine. Allopurinol has a plasma half-life of about 1 to 2 hours.



Oxipurinol is a less potent inhibitor of xanthine oxidase than allopurinol, but the plasma half-life of oxipurinol is far more prolonged. Estimates range from 13 to 30 hours in man. Therefore effective inhibition of xanthine oxidase is maintained over a 24 hour period with a single daily dose of Zyloric. Patients with normal renal function will gradually accumulate oxipurinol until a steady-state plasma oxipurinol concentration is reached. Such patients, taking 300 mg of allopurinol per day will generally have plasma oxipurinol concentrations of 5-10 mg/litre.



Oxipurinol is eliminated unchanged in the urine but has a long elimination half-life because it undergoes tubular reabsorption. Reported values for the elimination half-life range from 13.6 hours to 29 hours. The large discrepancies in these values may be accounted for by variations in study design and/or creatinine clearance in the patients.



Pharmacokinetics in patients with renal impairment.



Allopurinol and oxipurinol clearance is greatly reduced in patients with poor renal function resulting in higher plasma levels in chronic therapy. Patients with renal impairment, where creatinine clearance values were between 10 and 20ml/min, showed plasma oxipurinol concentrations of approximately 30mg/litre after prolonged treatment with 300 mg allopurinol per day. This is approximately the concentration which would be achieved by doses of 600 mg/day in those with normal renal function. A reduction in the dose of Zyloric is therefore required in patients with renal impairment.



Pharmacokinetics in elderly patients.



The kinetics of the drug are not likely to be altered other than due to deterioration in renal function (see Pharmocokinetics in patients with renal impairment).



5.3 Preclinical Safety Data



A. Mutagenicity



Cytogenetic studies show that allopurinol does not induce chromosome aberrations in human blood cells in vitro at concentrations up to 100 micrograms/ml and in vivo at doses up to 600 mg/day for mean period of 40 months.



Allopurinol does not produce nitraso compounds in vitro or affect lymphocyte transformation in vitro.



Evidence from biochemical and other cytological investigations strongly suggests that allopurinol has no deleterious effects on DNA at any stage of the cell cycle and is not mutagenic.



B. Carcinogenicity



No evidence of carcinogenicity has been found in mice and rats treated with allopurinol for up to 2 years.



C. Teratogenicity



One study in mice receiving intraperitoneal doses of 50 or 100 mg/kg on days 10 or 13 of gestation resulted in foetal abnormalities, however in a similar study in rats at 120 mg/kg on day 12 of gestation no abnormalities were observed. Extensive studies of high oral doses of allopurinol in mice up to 100 mg/kg/day, rats up to 200 mg/kg/day and rabbits up to 150 mg/kg/day during days 8 to 16 of gestation produced no teratogenic effects.



An in vitro study using foetal mouse salivary glands in culture to detect embryotoxicity indicated that allopurinol would not be expected to cause embryotoxicity without also causing maternal toxicity.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Lactose



Maize Starch



Povidone



Magnesium Stearate



Purified Water



6.2 Incompatibilities



None known.



6.3 Shelf Life



5 years.



6.4 Special Precautions For Storage



Do not store above 25°C. Store in the original package



6.5 Nature And Contents Of Container



Zyloric 100mg Tablets



PVC/aluminium foil blister pack



Zyloric-300 Tablets



PVC/aluminium foil blister pack



6.6 Special Precautions For Disposal And Other Handling



No special instructions.



Administrative Data


7. Marketing Authorisation Holder



Aspen Europe GmbH,



Industriestrasse 32-36,



D-23843 Bad Oldesloe,



Germany



8. Marketing Authorisation Number(S)



PL 00003/5207R – Zyloric 100mg Tablets



PL 00003/0092R – Zyloric-300 Tablets



9. Date Of First Authorisation/Renewal Of The Authorisation












Zyloric 100mg Tablets




Zyloric-300 Tablets




MAA: 20.03.80




14.07.80




Renewal: 06.06.90




18.02.91




Renewal: 14.11.95




25.11.98



10. Date Of Revision Of The Text



13 October 2009



11. Legal Status


POM




Thursday, 12 April 2012

Isoniazida Fabra




Isoniazida Fabra may be available in the countries listed below.


Ingredient matches for Isoniazida Fabra



Isoniazid

Isoniazid is reported as an ingredient of Isoniazida Fabra in the following countries:


  • Argentina

International Drug Name Search

Sulfatol Cleanser





Dosage Form: topical solution
Sulfatol™ Cleanser (Sodium Sulfacetamide 10%, and Sulfur 5% in a Urea Vehicle)

Rx Only



Sulfatol Cleanser Description


Sodium Sulfacetamide is a sulfonamide with antibacterial activity. Sulfur acts as a keratolytic agent. Chemically, sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:



Each mL of Sulfatol™ Cleanser (Sodium Sulfacetamide 10%, and Sulfur 5% in a Urea vehicle) contains 100 mg of Sodium Sulfacetamide and 50 mg of Sulfur in an emulsion base containing Urea 10%, BHT, Cetyl Alcohol, Disodium EDTA, Fragrance, Disodium Oleamido MEA Sulfosuccinate, Glyceryl and PEG-100 Stearate, Magnesium Aluminum Silicate, Methylparaben, Propylparaben, Sodium Cocoyl Isethionate, Sodium Methyl Cocoyl Taurate, Sodium Thiosulfate, Stearyl Alcohol, Purified Water, Xanthan Gum.



Sulfatol Cleanser - Clinical Pharmacology


The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.



INDICATIONS


Sulfatol™ Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.



Contraindications


Sulfatol™ Cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sulfatol™ Cleanser is not to be used by patients with kidney disease.



Warnings


Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.


FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of reach of children. Keep bottle tightly closed.



Precautions



General


If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris but patients should be cautioned about the possibility.



Information for Patients


Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs rinse with water. If excessive irritation develops, discontinue use and consult your physician.



Carcinogenesis, Mutagenesis, and Impairment of Fertility


Long-term studies in animals have not been performed to evaluate carcinogenic potential.



Pregnancy


Category C

Animal reproduction studies have not been conducted with Sulfatol™ Cleanser. It also is not known whether Sulfatol™ Cleanser can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sulfatol™ Cleanser should be given to a pregnant woman only if clearly needed.



Nursing Mothers


It is not known whether sodium sulfacetamide is excreted in human milk following topical use of Sulfatol™ Cleanser. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sulfatol™ Cleanser is administered to a nursing woman.



Pediatric Use


Safety and effectiveness in children under the age of 12 have not been established.



Adverse Reactions


Although rare, sodium sulfacetamide may cause local irritation.



Sulfatol Cleanser Dosage and Administration



Sulfatol™ Cleanser


Wash affected area once or twice daily or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off cleanser sooner or using less often.



How is Sulfatol Cleanser Supplied


Sulfatol™ Cleanser is available in a 355 mL bottle. NDC 51991-173-26



Storage


Store at 25° C (77° F); excursions permitted to 15°-30° C (59°-86° F). See USP Controlled Room Temperature.


Protect from freezing.



Distributed by: Breckenridge Pharmaceutical, Inc., Boca Raton, FL 33487

Manufactured by: Groupe Parima Inc., Montréal, QC Canada H4S 1X6


06/07



PRINCIPAL DISPLAY PANEL - 355 mL Bottle Carton


Breckenridge

Pharmaceutical, Inc.


NDC 51991-173-26


Sulfatol™ Cleanser

Sodium Sulfacetamide 10%, Sulfur 5% in a Urea vehicle


Skin Cleanser

For The Topical Treatment Of


  • Acne Vulgaris

  • Acne Rosacea

  • Seborrheic Dermatitis

Rx ONLY


Net Wt. 355 mL










Sulfatol Cleanser 
sulfacetamide sodium and sulfur  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)51991-173
Route of AdministrationTOPICALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Sulfacetamide Sodium (Sulfacetamide)Sulfacetamide Sodium100 mg  in 1 mL
Sulfur (Sulfur)Sulfur50 mg  in 1 mL


































Inactive Ingredients
Ingredient NameStrength
Butylated Hydroxytoluene 
Cetyl Alcohol 
Edetate Disodium 
Glyceryl Monostearate 
Disodium Oleamido MEA-Sulfosuccinate 
Polyoxyl 100 Stearate 
Magnesium Aluminum Silicate 
Methylparaben 
Propylparaben 
Sodium Cocoyl Isethionate 
Sodium Thiosulfate 
Stearyl Alcohol 
Urea 
Water 
Xanthan Gum 


















Product Characteristics
ColorYELLOW (light-yellow)Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
151991-173-261 BOTTLE In 1 BOXcontains a BOTTLE
1355 mL In 1 BOTTLEThis package is contained within the BOX (51991-173-26)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
UNAPPROVED DRUG OTHER03/01/200509/30/2011


Labeler - Breckenridge Pharmaceutical, Inc. (150554335)









Establishment
NameAddressID/FEIOperations
Groupe Parima252437850MANUFACTURE
Revised: 11/2010Breckenridge Pharmaceutical, Inc.

More Sulfatol Cleanser resources


  • Sulfatol Cleanser Side Effects (in more detail)
  • Sulfatol Cleanser Use in Pregnancy & Breastfeeding
  • Sulfatol Cleanser Drug Interactions
  • Sulfatol Cleanser Support Group
  • 18 Reviews for Sulfatol - Add your own review/rating


  • Sulfatol Cleanser Emulsion MedFacts Consumer Leaflet (Wolters Kluwer)

  • Rosula CLK Kit MedFacts Consumer Leaflet (Wolters Kluwer)

  • Sulfatol Gel MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Sulfatol Cleanser with other medications


  • Acne
  • Rosacea
  • Seborrheic Dermatitis

Monday, 9 April 2012

Gelato Chlorhexidine Rinse




Generic Name: chlorhexidine gluconate

Dosage Form: oral rinse
Gelato Chlorhexidine Distilled Water, Glycerin, Polysorbate 20, Poloxamer 407, Sodium Saccharin, Mint Flavor, FD and C Blue #1

The effect of Chlohexidrine Gluconate Oral Rinse on periodontitis has not been determined. An increase in supragingival calculus was not noted in clinical testing in chlohexidine gluconate oral rinse users compared with control users. It is not known if Chlorhexidine Gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Hypersensitivity and generalized allergic reactions have occured. read CONTRAINDICATIONS indicated on the insert inside the box.



To open, press down while turning cap. To seal, turn until cap clicks and is tight. Fill dosage cup to the fill like (150ml). Swish in your mouth undiluted for 30 seconds, the spit out. Use after breakfast and before bedtime. Or, use as prescribed by your dentist.


Chlorhexidine Gluconate Oral Rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. For patients having coexisting gingivitis and periodontitis, read PRECAUTIONS indicated on the insert inside the box.

Store at controlled room temperature 68-77F (20-25C). Protect from freezing.



0.12% Chlorhexidine Gluconate



Antigingivitis











GELATO CHLOROHEXIDINE 
chlorhexidine gluconate  rinse










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)68400-500
Route of AdministrationDENTAL, TOPICAL, ORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CHLORHEXIDINE GLUCONATE (CHLORHEXIDINE)CHLORHEXIDINE GLUCONATE56.76 mL  in 473 mL
















Inactive Ingredients
Ingredient NameStrength
Water 
Glycerin 
FD&C BLUE NO. 1 
SACCHARIN SODIUM 
POLYSORBATE 20 
POLOXAMER 407 


















Product Characteristics
Color    Score    
ShapeSize
FlavorMINTImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
168400-500-16473 mL In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other03/31/2010


Labeler - Deepak Products, inc. (124886743)









Establishment
NameAddressID/FEIOperations
Deepak Products, inc.124886743manufacture
Revised: 04/2011Deepak Products, inc.




More Gelato Chlorhexidine Rinse resources


  • Gelato Chlorhexidine Rinse Side Effects (in more detail)
  • Gelato Chlorhexidine Rinse Use in Pregnancy & Breastfeeding
  • Gelato Chlorhexidine Rinse Support Group
  • 1 Review for Gelato Chlorhexidine - Add your own review/rating


Compare Gelato Chlorhexidine Rinse with other medications


  • Gingivitis
  • Mucositis
  • Periodontitis

Thalidomide Celgene 50 mg Hard Capsules





1. Name Of The Medicinal Product



Thalidomide Celgene 50 mg hard capsules


2. Qualitative And Quantitative Composition



Each capsule contains 50 mg of thalidomide.



Excipient:



Each capsule contains 257.2 mg of anhydrous lactose.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Hard capsule.



White opaque capsules marked “Thalidomide 50 mg Celgene”.



4. Clinical Particulars



4.1 Therapeutic Indications



Thalidomide Celgene in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged



Thalidomide Celgene is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).



4.2 Posology And Method Of Administration



Thalidomide treatment must be initiated and monitored under the supervision of physicians with expertise in managing immunomodulatory or chemotherapeutic agents and a full understanding of the risks of thalidomide therapy and monitoring requirements (see section 4.4).



Recommended posology in adults:



The recommended oral dose is 200 mg per day.



A maximum number of 12 cycles of 6 weeks should be used.



Thalidomide Celgene should be taken as a single dose at bedtime, to reduce the impact of somnolence. Thalidomide Celgene can be taken with or without food.



Patients should be monitored for: thromboembolic events; peripheral neuropathy; rash/skin reactions; bradycardia, syncope and somnolence (see sections 4.4 and 4.8). Dose delay, reduction or discontinuation, dependent upon the NCI CTC grade, may be necessary.



Thromboembolic events:



Thromboprophylaxis should be administered for at least the first 5 months of treatment especially in patients with additional thrombotic risk factors. Prophylactic antithrombotic medicinal products, such as low molecular weight heparins or warfarin, should be recommended. The decision to take antithrombotic prophylactic measures should be made after careful assessment of an individual patient's underlying risk factors (see sections 4.4, 4.5 and 4.8).



If the patient experiences any thromboembolic events, treatment must be discontinued and standard anticoagulation therapy started. Once the patient has been stabilised on the anticoagulation treatment and any complications of the thromboembolic event have been managed, the thalidomide treatment may be restarted at the original dose dependent upon a benefit risk assessment. The patient should continue anticoagulation therapy during the course of thalidomide treatment.



Peripheral neuropathy:



Dose modifications due to peripheral neuropathy are described in Table 1.



Table 1: Recommended dose modifications for Thalidomide Celgene related neuropathy in first line treatment of multiple myeloma.














Severity of neuropathy




Modification of dose and regimen




Grade 1 (paraesthesia, weakness and/or loss of reflexes) with no loss of function




Continue to monitor the patient with clinical examination. Consider reducing dose if symptoms worsen. However, dose reduction is not necessarily followed by improvement of symptoms.




Grade 2 (interfering with function but not with activities of daily living)




Reduce dose or interrupt treatment and continue to monitor the patient with clinical and neurological examination. If no improvement or continued worsening of the neuropathy, discontinue treatment. If the neuropathy resolves to Grade 1 or better, the treatment may be restarted, if the benefit/risk is favourable.




Grade 3 (interfering with activities of daily living)




Discontinue treatment




Grade 4 (neuropathy which is disabling)




Discontinue treatment



Elderly:



No specific dose adjustments are recommended for the elderly.



Patients with renal or hepatic impairment:



Thalidomide Celgene has not formally been studied in patients with impaired renal or hepatic function. No specific dose recommendations for these patient populations are available. Patients with severe organ impairment should be carefully monitored for adverse reactions.



Paediatric patients:



Thalidomide Celgene is not recommended for use in children below 18 years of age as safety and efficacy have not been established.



4.3 Contraindications



− Hypersensitivity to thalidomide or to any of the excipients.



− Pregnant women (see section 4.6).



− Women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see sections 4.4 and 4.6).



− Patients unable to follow or comply with the required contraceptive measures (see section 4.4).



4.4 Special Warnings And Precautions For Use





Teratogenic effects:



Thalidomide is a powerful human teratogen, inducing a high frequency of severe and life-threatening birth defects. Thalidomide must never be used by women who are pregnant or by women who could become pregnant unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met. The conditions of the Thalidomide Celgene Pregnancy Prevention Programme must be fulfilled for all male and female patients.



Criteria for women of non-childbearing potential:



A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:



• Age



• Premature ovarian failure confirmed by a specialist gynaecologist.



• Previous bilateral salpingo-oophorectomy, or hysterectomy.



• XY genotype, Turner's syndrome, uterine agenesis.



*Amenorrhoea following cancer therapy does not rule out childbearing potential.



Counselling:



For women of childbearing potential, thalidomide is contraindicated unless all of the following are met:



• She understands the teratogenic risk to the unborn child



• She understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment



• Even if a woman of childbearing potential has amenorrhea she must follow all the advice on effective contraception



• She should be capable of complying with effective contraceptive measures



• She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy



• She understands the need to commence the treatment as soon as thalidomide is dispensed following a negative pregnancy test



• She understands the need and accepts to undergo pregnancy testing every 4 weeks



• She acknowledges that she understands the hazards and necessary precautions associated with the use of thalidomide.



As thalidomide is found in semen, male patients taking thalidomide must meet the following conditions:



• Understand the teratogenic risk if engaged in sexual activity with a pregnant woman.



• Understand the need for the use of a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception.



The prescriber must ensure that:



• The patient complies with the conditions of the Thalidomide Celgene Pregnancy Prevention Programme



• The patient confirms that he (she) understand the aforementioned conditions.



Contraception:



Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and during 4 weeks after thalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis. If not established on effective contraception, the patient must be referred preferably to an appropriately trained healthcare professional for contraceptive advice in order that contraception can be initiated.



The following can be considered to be examples of effective methods of contraception:



• Subcutaneous hormonal implant



• Levonorgestrel-releasing intrauterine system (IUS)



• Medroxyprogesterone acetate depot



• Tubal sterilisation



• Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses



• Ovulation inhibitory progesterone-only pills (i.e., desogestrel)



Because of the increased risk of venous thromboembolism in patients with multiple myeloma, combined oral contraceptive pills are not recommended (see section 4.5). If a patient is currently using combined oral contraception the patient should switch to one of the effective method listed above. The risk of venous thromboembolism continues for 4−6 weeks after discontinuing combined oral contraception.



Pregnancy testing:



Medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/ml must be performed for women of childbearing potential as outlined below. This requirement includes women of childbearing potential who practice absolute and continuous abstinence.



Prior to starting treatment



A medically supervised pregnancy test should be performed during the consultation, when thalidomide is prescribed or in the 3 days prior to the visit to the prescriber once the patient had been using effective contraception for at least 4 weeks. The test should ensure the patient is not pregnant when she starts treatment with thalidomide.



Follow-up and end of treatment



A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment. These pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.



Men:



As thalidomide is found in semen, male patients must use condoms during treatment and for 1 week after dose interruption and/or cessation of treatment if their partner is pregnant or is of childbearing potential not using effective contraception.



Prescribing and dispensing restrictions:



For women of childbearing potential, prescriptions of Thalidomide Celgene should be limited to 4 weeks of treatment and continuation of treatment requires a new prescription. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of thalidomide should occur within a maximum of 7 days of the prescription.



For all other patients, prescriptions of Thalidomide Celgene should be limited to 12 weeks and continuation of treatment requires a new prescription.



Additional precautions:



Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.



Patients should not donate blood or semen during therapy or for 1 week following discontinuation of thalidomide.



Educational materials:



In order to assist patients in avoiding foetal exposure to thalidomide and to provide additional important safety information, the Marketing Authorisation holder will provide educational material to healthcare professionals. The Thalidomide Celgene Pregnancy Prevention Programme reinforces the warnings about the teratogenicity of thalidomide, provides advice on contraception before therapy is started and provides guidance on the need for pregnancy testing. Full patient information about the teratogenic risk and the pregnancy prevention measures as specified in the Thalidomide Celgene Pregnancy Prevention Programme should be given by the physician to women of childbearing potential and, as appropriate, to male patients.



Cardiovascular disorders



Myocardial Infarction:



Myocardial infarction (MI) has been reported in patients receiving thalidomide, particularly in those with known risk factors. Patients with known risk factors for MI, including prior thrombosis, should be closely monitored and action should be taken to try to minimise all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia).



Venous and arterial thromboembolic events:



Patients treated with thalidomide have an increased risk of venous thromboembolism (such as deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (such as myocardial infarction and cerebrovascular event), see section 4.8. The risk appears to be greatest during the first 5 months of therapy. Thromboprophylaxis and dosing/anticoagulation therapy recommendations are provided in section 4.2.



Previous history of thromboembolic events or concomitant administration of erythropoietic agents or other agents such as hormone replacement therapy, may also increase thromboembolic risk in these patients. Therefore, these agents should be used with caution in multiple myeloma patients receiving thalidomide with prednisone and melphalan. Particularly, a haemoglobin concentration above 12g/dl should lead to discontinuation of erythropoietic agents. Action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension and hyperlipidaemia).



Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling.



Peripheral neuropathy:



Peripheral neuropathy is a very common, potentially severe, adverse reaction to treatment with thalidomide that may result in irreversible damage (see section 4.8). In a phase 3 study, the median time to first neuropathy event was 42.3 weeks.



If the patient experiences peripheral neuropathy, follow the dose and schedule modification instruction provided in section 4.2.



Careful monitoring of patients for symptoms of neuropathy is recommended. Symptoms include paraesthesia, dysaesthesia, discomfort, abnormal co-ordination or weakness.



It is recommended that clinical and neurological examinations are performed in patients prior to starting thalidomide therapy, and that routine monitoring is carried out regularly during treatment.



Medicinal products known to be associated with neuropathy should be used with caution in patients receiving thalidomide (see section 4.5).



Thalidomide may also potentially aggravate existing neuropathy and should therefore not be used in patients with clinical signs or symptoms of peripheral neuropathy unless the clinical benefits outweigh the risks.



Syncope and bradycardia:



Patients should be monitored for syncope and bradycardia and dose reduction or discontinuation may be required.



Skin reactions:



If at anytime the patient experiences a toxic skin reaction e.g. Stevens-Johnson Syndrome, the treatment should be discontinued permanently.



Somnolence:



Thalidomide frequently causes somnolence. Patients should be instructed to avoid situations where somnolence may be a problem and to seek medical advice before taking other medicinal products known to cause somnolence. Patients should be monitored and dose reduction may be required.



Patients should be advised as to the possible impairment of mental and/or physical abilities required for the performance of hazardous tasks (see section 4.7).



Tumour lysis syndrome:



The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.



Patients with renal or hepatic impairment:



Studies conducted in healthy subjects and patients with multiple myeloma suggest that thalidomide is not influenced to any significant extent by renal or hepatic function (see section 5.2). However, this has not formally been studied in patients with impaired renal or hepatic function; therefore patients with severe renal or hepatic impairment should be carefully monitored for any adverse effects.



Lactose intolerance:



The capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Thalidomide is a poor substrate for cytochrome P450 isoenzymes and therefore clinically important interactions with medicinal products metabolized by this enzyme system are unlikely. Non-enzymatic hydrolysis suggests that the potential for drug-drug interactions with thalidomide is low.



Increase of sedative effects of other medicinal products:



Thalidomide has sedative properties thus may enhance the sedation induced by anxiolytics, hypnotics, antipsychotics, H1 anti-histamines, opiate derivatives, barbiturates and alcohol. Caution should be used when thalidomide is given in combination with medicinal products that cause drowsiness.



Bradycardic effect:



Due to thalidomide's potential to induce bradycardia, caution should be exercised with medicinal products having the same pharmacodynamic effect such as active substances known to induce torsade de pointes, beta blockers or anticholinesterase agents.



Medicinal products known to cause peripheral neuropathy:



Medicinal products known to be associated with peripheral neuropathy (e.g. vincristine and bortezomib) should be used with caution in patients receiving thalidomide.



Hormonal contraceptives:



Thalidomide does not interact with hormonal contraceptives. In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 0.75 mg of ethinyl estradiol were studied. The results were similar with and without co-administration of thalidomide 200 mg/day to steady-state levels. However, combined hormonal contraceptives are not recommended due to the increased risk of venous thrombo-embolic disease.



Warfarin:



Multiple dose administration of 200 mg thalidomide q.d. for 4 days had no effect on the international normalized ratio (INR) in healthy volunteers. However, due to the increased risk of thrombosis in cancer patients, and a potentially accelerated metabolism of warfarin with corticosteroids, close monitoring of INR values is advised during thalidomide-prednisone combination treatment as well as during the first weeks after ending these treatments.



Digoxin:



Thalidomide does not interact with digoxin. In 18 healthy male volunteers, multiple dose administration of 200 mg thalidomide had no apparent effect on the single dose pharmacokinetics of digoxin. In addition, single dose administration of 0.5 mg digoxin had no apparent effect on thalidomide pharmacokinetics. It is not known whether the effect will be different in multiple myeloma patients.



4.6 Pregnancy And Lactation



Thalidomide Celgene is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see section 4.3)



Thalidomide is a powerful human teratogen, inducing a high frequency (about 30%) of severe and live-threatening birth defects such as: ectromelia (amelia, phocomelia, hemimelia) of the upper and/or lower extremities, microtia with abnormality of the external acoustic meatus (blind or absent), middle and internal ear lesions (less frequent), ocular lesions (anophthalmia, microphthalmia), congenital heart disease, renal abnormalities. Other less frequent abnormalities have also been described.



Women of childbearing potential:



Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and during 4 weeks after thalidomide therapy (see section 4.4).



If pregnancy occurs in a woman treated with thalidomide, treatment must be stopped immediately and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice.



Male patients with female partners of childbearing potential:



As thalidomide is found in semen, male patients must use condoms during treatment and for 1 week after dose interruption and/or cessation of treatment when having sexual intercourse with a pregnant woman or with a woman with childbearing potential who is not using effective contraception.



If pregnancy occurs in a partner of male patient taking thalidomide, the female partner should be referred to a physician specialised or experienced in teratology for evaluation and advice.



Lactation:



It is unknown whether thalidomide is excreted in human breast milk. Animal studies have shown excretion of thalidomide in breast milk. Therefore breast-feeding should be discontinued during therapy with thalidomide.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed.



However thalidomide may cause somnolence and blurred vision (see section 4.8). If affected, patients should be instructed not to drive cars, use machines or perform hazardous tasks while being treated with thalidomide.



4.8 Undesirable Effects



Most patients taking thalidomide can be expected to experience adverse reactions. The most commonly observed adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone are: neutropenia, leukopenia, constipation, somnolence, paraesthesia, peripheral neuropathy, anaemia, lymphopenia, thrombocytopenia, dizziness, dysaesthesia, tremor and peripheral oedema.



The clinically important adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone or dexamethasone include: deep vein thrombosis and pulmonary embolism, peripheral neuropathy, severe skin reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis, syncope, bradycardia, and dizziness (see sections 4.2, 4.4 and 4.5).



Table 2 contains only the adverse reactions for which a causal relationship with medicinal product treatment could reasonably be established. Frequencies given are based on the observations during a pivotal comparative clinical study investigating the effect of thalidomide in combination with melphalan and prednisone in previously untreated multiple myeloma patients. In addition to the adverse reactions noted in the pivotal study, adverse reactions related to thalidomide in combination with dexamethasone and also those based on post-marketing experience with the medicinal product are provided after Table 2.



Frequencies are defined as: very common (



Table 2: Frequency of adverse reactions with thalidomide in combination with melphalan and prednisone





































System Organ Class




Very Common




Common




Cardiac disorders




 



 




Cardiac failure



Bradycardia




Blood and lymphatic system disorders




Neutropenia



Leukopenia



Anaemia



Lymphopenia



Thrombocytopenia




 



 




Nervous system disorders




Peripheral neuropathy*



Tremor



Dizziness



Paraesthesia



Dysaesthesia



Somnolence




Abnormal coordination



 




Respiratory, thoracic and mediastinal disorders




 



 




Pulmonary embolism*



Interstitial lung disease



Bronchopneumopathy



Dyspnea




Gastrointestinal disorders




Constipation




Vomiting



Dry mouth




Skin and subcutaneous tissue disorders




 



 




Toxic skin eruption



Rash



Dry skin




Infections and infestations




 



 




Pneumonia




Vascular disorders




 



 




Deep vein thrombosis*




General disorders and administration site conditions




Peripheral oedema



 




Pyrexia



Asthenia



Malaise




Psychiatric disorders




 



 




Confusional state



Depression



* - See detailed section below



In addition to the adverse reactions outlined above thalidomide in combination with dexamethasone in other clinical studies led to the very common adverse reaction of fatigue; common adverse reactions of transient ischaemic event, syncope, vertigo, hypotension, mood altered, anxiety, blurred vision, nausea and dyspepsia; and uncommon adverse reactions of cerebrovascular accident, diverticular perforation, peritonitis, orthostatic hypotension and bronchitis.



Additional adverse reactions related to post-marketing experience with thalidomide and not seen in the pivotal study include: toxic epidermal necrolysis, intestinal obstruction, hypothyroidism, sexual dysfunction, tumour lysis syndrome, gastro-intestinal perforations, hypersensitivity, hearing impaired or deafness, renal failure, myocardial infarction and worsening of Parkinson's disease symptoms.



Blood and lymphatic system disorders:



Adverse reactions for haematological disorders are provided compared to the comparator arm, as the comparator has a significant effect on these disorders (Table 3)



Table 3: Comparison of haematological disorders for the melphalan, prednisone (MP) and melphalan, prednisone, thalidomide (MPT) combinations in study IFM 99-06 (see section 5.1)



























 


n (% of patients)


 

 


MP (n=193)




MPT (n=124)



 


Grades 3 and 4*


 


Neutropenia




57 (29.5)




53 (42.7)




Leukopenia




32 (16.6)




32 (25.8)




Anaemia




28 (14.5)




17 (13.7)




Lymphopenia




14 (7.3)




15 (12.1)




Thrombocytopenia




19 (9.8)




14 (11.3)



* WHO Criteria



Additional adverse reactions from post-marketing experience with thalidomide and not seen in the pivotal study include febrile neutropenia and pancytopenia.



Teratogenicity:



The risk of intra-uterine death or severe birth defects, primarily phocomelia, is extremely high. Thalidomide must not be used at any time during pregnancy (see sections 4.4 and 4.6).



Venous and arterial thromboembolic events:



An increased risk of venous thromboembolism (such as deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (such as myocardial infarction and cerebrovascular event) has been reported in patients treated with thalidomide (see section 4.4).



Peripheral neuropathy:



Peripheral neuropathy is a very common, potentially severe, adverse reaction of treatment with thalidomide that may result in irreversible damage (see section 4.4). Peripheral neuropathy generally occurs following chronic use over a period of months. However, reports following relatively short-term use also exist. Incidence of neuropathy events leading to discontinuation, dose reduction or interruption increases with cumulative dose and duration of therapy. Symptoms may occur some time after thalidomide treatment has been stopped and may resolve slowly or not at all.



4.9 Overdose



Eighteen cases of overdose have been reported in the literature concerning doses up to 14.4 g. No fatalities have been reported and all overdose patients recovered without sequelae. There is no specific antidote for a thalidomide overdose. In the event of an overdose, the patient's vital signs should be monitored and appropriate supportive care given to maintain blood pressure and respiratory status.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: immunosuppressive agent, ATC code: L04AX 02.



Thalidomide has a chiral centre and is used clinically as a racemate of (+)-(R)- and (-)-(S)-thalidomide. The spectrum of activity of thalidomide is not fully characterised.



Thalidomide shows immunomodulatory anti-inflammatory and potential anti-neoplastic activities. Data from in vitro studies and clinical trials suggest that the immunomodulatory, anti-inflammatory and anti-neoplastic effects of thalidomide may be related to suppression of excessive tumour necrosis factor-alpha (TNF-α) production, down-modulation of selected cell surface adhesion molecules involved in leukocyte migration and anti-angiogenic activity. Thalidomide is also a non-barbiturate centrally active hypnotic sedative. It has no anti-bacterial effects.



Clinical efficacy:



Results from IFM 99-06, a Phase 3, randomised, open label, parallel group, multicentre study have demonstrated a survival advantage when thalidomide is used in combination with melphalan and prednisone for 12 cycles of 6 weeks in the treatment of newly diagnosed multiple myeloma patients. In this study the age range of patients was 65-75 years, with 41% (183/447) of patients 70 years old or older. The median dose of thalidomide was 217 mg and>40% of patients received 9 cycles. Melphalan and prednisone were dosed at 0.25 mg/kg/day and 2 mg/kg/day respectively on days 1 to 4 of each 6 weeks cycle.



Further to the per protocol analysis, an update was conducted for the IFM 99-06 study providing an additional 15 months follow-up data. The median overall survival (OS) was 51.6 ± 4.5 and 33.2 ± 3.2 months in the MPT and MP groups, respectively (97.5% CI 0.42 to 0.84). This 18 month difference was statistically significant with a hazard ratio of reduction of risk of death in the MPT arm of 0.59, 97.5% confidence interval of 0.42-0.84 and p-value of <0.001 (see Figure 1).



Figure 1: Overall survival according to treatment





5.2 Pharmacokinetic Properties



Absorption:



Absorption of thalidomide is slow after oral administration. The maximum plasma concentrations are reached 1-5 hours after administration. Co-administration of food delayed absorption but did not alter the overall extent of absorption.



Distribution:



The plasma protein binding of the (+)-(R) and (-)-(S) enantiomers was found to be 55% and 65% respectively. Thalidomide is present in the semen of male patients at levels similar to plasma concentrations. Therefore, because of the known severe teratogenic effects of the product, during treatment with thalidomide and for 1 week after stopping the treatment, male patients must use condoms if their partner is pregnant or is of childbearing potential not using effective contraception (see section 4.4).



Metabolism:



Thalidomide is metabolised almost exclusively by non-enzymatic hydrolysis. In plasma, unchanged thalidomide represents 80% of the circulatory components. Unchanged thalidomide was a minor component (<3% of the dose) in urine. In addition to thalidomide, hydrolytic products N-(o-carboxybenzoyl) glutarimide and phthaloyl isoglutamine formed via non-enzymatic processes are also present in plasma and in majority in urine. Oxidative metabolism does not contribute significantly to the overall metabolism of thalidomide. There is minimal cytochrome P450 catalysed hepatic metabolism of thalidomide. There are in vitro data indicating that prednisone may give rise to enzyme induction which could reduce the systemic exposure of concomitantly used medicinal products. The in vivo relevance of these findings is unknown.



Elimination:



The mean elimination half-life of thalidomide in plasma following single oral doses between 50 mg and 400 mg was 5.5 to 7.3 hours. Total systemic exposure (AUC) is proportional to dose at single-dose conditions. No time dependency of the pharmacokinetics has been observed. Following a single oral dose of 400mg of radio-labelled thalidomide, the total mean recovery was 93.6% of the administered dose by Day 8. The majority of the radioactive dose was excreted within 48 hour following dose administration. The major route of excretion was via the urine (>90%) while faecal excretion was minor.



There is a linear relationship between body weight and estimated thalidomide clearance; in MM patients with body weight from 47-133kg, thalidomide clearance ranged from approximately 6-12 L/h, representing an increase in thalidomide clearance of 0.621 L/h per 10kg body weight increase. However, the distribution of thalidomide is not influenced by age, gender, renal function and blood chemistry variables, to any significant level.



Hepatic and renal insufficiency:



The extent of thalidomide metabolism by the liver cytochrome P450 system is minimal and intact thalidomide is not excreted by the kidney. Measures of renal function (CLcr) and liver function (blood chemistry) indicate minimal effect of kidney and liver function on the pharmacokinetics of thalidomide. As such the metabolism of thalidomide is not expected to be affected by hepatic or renal dysfunction. Data from patients with end-stage renal disease suggest no impact of kidney function on thalidomide pharmacokinetics. However, considering that pharmacologically active metabolites are eliminated via urine, it is advised that patients with severe renal impairment should be carefully monitored for any adverse reactions.



5.3 Preclinical Safety Data



In the male dog, after one year of dosing, reversible bile plugs in canaliculi were observed at exposures greater than 1.9 fold the human exposure.



Decreased platelet counts were noted in the mouse and rat studies. The latter appears to be related to thalidomide and occurred at exposures greater than 2.4 fold the human exposure. This decrease did not result in clinical signs.



In a one-year dog study, enlarged and/or blue discoloration of mammary glands and prolonged estrus were observed in females at exposures equal to 1.8 or greater than 3.6-fold the human exposure, respectively. The relevance to humans is unknown.



The effect of thalidomide on thyroid function was assessed in both rats and dogs. No effects were observed in dogs; however in rats, there was an apparent dose-dependent decrease in total and free T4 that was more consistent in the female.



No mutagenic or genotoxic effect has been revealed when thalidomide was assayed in a standard battery of genotoxicity tests. No evidence of carcinogenicity was observed at exposures approximately 15, 13 and 39 times the estimated clinical AUC at the recommended starting dose in mice, male rats and female rats respectively.



Animal studies have demonstrated differences in species susceptibility to the teratogenic effects of thalidomide. In humans, thalidomide is a proven teratogen.



A study in rabbits demonstrated no effect on fertility indices in males or females although testicular degeneration was observed in males.



A peri and postnatal toxicity study performed in rabbits with thalidomide administered at doses up to 500 mg/kg/day resulted in abortions, increased stillbirths and decreased pup viability during lactation. Pups from mothers treated with thalidomide had increased abortions, reduced body weight gain, alterations in learning and memory, decreased fertility, and reduced pregnancy index.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Capsule contents:



Anhydrous lactose



Microcrystalline cellulose



Crospovidone (Type A)



Povidone (K90)



Stearic acid



Colloidal anhydrous silica



Capsule shell:



Gelatin



Titanium dioxide (E171)



Printing ink:



Shellac



Black iron oxide (E172)



Propylene glycol



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



3 years.



6.4 Special Precautions For Storage



This medicinal product does not require any special storage conditions.



6.5 Nature And Contents Of Container



PVC/PE/Aclar/aluminium blister containing 14 capsules



Pack sizes: 28 capsules (two blisters) in a wallet card.



6.6 Special Precautions For Disposal And Other Handling



All unused capsules should be returned to the pharmacist at the end of treatment.



7. Marketing Authorisation Holder



Celgene Europe Limited



1 Longwalk Road



Stockley Park



Uxbridge



UB11 1DB



United Kingdom



8. Marketing Authorisation Number(S)



EU/1/08/443/001



9. Date Of First Authorisation/Renewal Of The Authorisation



16/04/2008



10. Date Of Revision Of The Text



03/08/2011



Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.